Cardiovascular diseases are the leading cause of global mortality. Over the past two decades, researchers have tried to provide novel solutions for end-stage heart failure to address cardiac transplantation hurdles such as donor organ shortage, chronic rejection, and life-long immunosuppression. Cardiac decellularized extracellular matrix (dECM) has been widely explored as a promising approach in tissue-regenerative medicine because of its remarkable similarity to the original tissue. Optimized decellularization protocols combining physical, chemical, and enzymatic agents have been developed to obtain the perfect balance between cell removal, ECM composition, and function maintenance. However, proper assessment of decellularized tissue composition is still needed before clinical translation. Recellularizing the acellular scaffold with organ-specific cells and evaluating the extent of cardiomyocyte repopulation is also challenging. This review aims to discuss the existing literature on decellularized cardiac scaffolds, especially on the advantages and methods of preparation, pointing out areas for improvement. Finally, an overview of the state of research regarding the application of cardiac dECM and future challenges in bioengineering a human heart suitable for transplantation is provided.

Corrosion inhibitors represent one of the most commonly used methods for significantly reducing the corrosion rate of metals and alloys. Adsorption inhibitors have a wide range of applications in cooling water systems, deicing solutions for aircrafts, airports and ways, etching and degreasing solutions, oil pipelines, paints and coatings and metal processing solutions. Adsorption corrosion inhibitors of metals and alloys are generally organic compounds that contain structures with heteroatoms (N, P, S, As, O) in their molecules, having lone pair electrons or π electrons in aromatic rings or multiple bonds. They enable relatively strong interactions between the metal atoms and organic molecules, resulting in a protective layer of organic molecules adsorbed at the metal–corrosive solution interface. Most molecules of active substances from drugs contain similar structures, which is why many drugs have been already tested as corrosion inhibitors. One of the major disadvantages of using drugs for this purpose is their particularly high price. To overcome this impediment, the possibility of using expired drugs as corrosion inhibitors has been investigated since 2009. The present paper is an exhaustive compilation of the scientific published papers devoted to the use of expired drugs as corrosion inhibitors in various aggressive solutions. The inhibitory efficiencies of expired drugs are presented as a function of the studied metal or alloy and the nature of the aggressive solution, as well as the concentration of the inhibitor in such a solution. Research has especially been focused on mild and carbon steel and less on stainless steel, as well as on some metals such as copper, zinc, nickel, tin and aluminum and its alloys. The experimental methods used to assess the inhibitory efficiencies of expired drugs are briefly discussed. Also, the available information on the stability of the active substances in the drugs is presented, although most authors were not concerned with this aspect. Finally, several actions are revealed that must be undertaken by researchers so that the results obtained in the study of the anticorrosive action of expired drugs can be applied at the industrial level and not remain only an academic concern.

Azelaic acid (AzA), a saturated dicarboxylic acid, is indicated for the treatment of acne vulgaris, rosacea, melasma, and post-inflammatory hyperpigmentation. Its antimicrobial, anti-inflammatory, and antimelanogenic properties support its use; however, its poor aqueous solubility and limited skin permeability constrain its optimal topical delivery. This review summarizes clinical evidence and advances in formulations—including conventional vehicles, polymeric/lipid nanocarriers, and deep eutectic solvent (DES) systems—to promote more effective and well-tolerated use. Across indications, 15–20% azelaic acid (AzA) formulations produced clinically meaningful improvements with mild, transient local irritation. For acne vulgaris, reductions in inflammatory and noninflammatory lesions were comparable to those of topical retinoids/adapalene, and tolerability was superior in some studies. For rosacea, the 15% gel formulation was comparable to metronidazole in reducing papules, pustules, and erythema while maintaining negligible systemic exposure. In melasma and other dyschromias, 20% cream demonstrated efficacy similar to hydroquinone, exhibiting a favorable safety profile. Advanced delivery systems, including liposomes, niosomes/ethosomes, nanostructured lipid carriers, microemulsions, nanosponges, and DES platforms, increased AzA solubilization, cutaneous deposition, and stability. This enabled dose-sparing strategies and improved adherence. Data on AzA cocrystals and ionic salts suggest additional control over release and irritation. AzA remains a versatile and well-tolerated dermatologic agent whose performance is strongly vehicle-dependent. Rational selection and engineering of carriers, particularly DES-integrated polymeric and lipid systems, can mitigate solubility and permeability limitations, enhance skin targeting, and reduce irritation in the treatment of acne and rosacea.

The tumor microenvironment (TME) influences cancer progression. Therefore, engineered TME models are being developed for fundamental research and anti-cancer drug screening. This paper reports the biofabrication of 3D-printed avascular structures that recapitulate several features of the TME. The tumor is represented by a hydrogel droplet uniformly loaded with breast cancer cells (10⁶ cells/mL); it is embedded in the same type of hydrogel containing primary cells—tumor-associated fibroblasts isolated from the peritumoral environment and peripheral blood mononuclear cells. Hoechst staining of cryosectioned tissue constructs demonstrated that cells remodeled the hydrogel and remained viable for weeks. Histological sections revealed heterotypic aggregates of malignant and peritumoral cells; moreover, the constituent cells proliferated in vitro. To investigate the interactions responsible for the experimentally observed cellular rearrangements, we built lattice models of the bioprinted constructs and simulated their evolution using Metropolis Monte Carlo methods. Although unable to replicate the complexity of the TME, the approach presented here enables the self-assembly and co-culture of several cell types of the TME. Further studies will evaluate whether the bioprinted constructs can evolve in vivo in animal models. If they become connected to the host vasculature, they may turn into a fully organized TME.

Cancer remains the second leading cause of death worldwide. Doxorubicin (DOX) is a cornerstone of hematologic malignancy treatment, but it is limited by its dose-dependent cardiotoxicity, leading to systolic and diastolic cardiac dysfunction and, ultimately, dilated hypokinetic cardiomyopathy. Cardio-oncology has emerged as a subspecialty addressing cardiovascular complications in cancer patients, highlighting preventive and therapeutic strategies to reduce cancer therapy-related cardiac dysfunction (CTRCD). Current approaches, including beta-blockers, renin–angiotensin system (RAS) inhibitors, and statins, offer partial cardioprotection. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, initially developed for type 2 diabetes mellitus (T2DM), demonstrate pleiotropic cardioprotective effects beyond glycemic control, including reduced oxidative stress, inflammation, and myocardial remodeling. This review explores the interplay between anthracycline therapy, particularly DOX, and cardiotoxicity while evaluating SGLT2 inhibitors as novel agents in cardio-oncology. Preclinical studies suggest SGLT2 inhibitors attenuate CTRCD by preserving mitochondrial function and inhibiting apoptosis, while clinical trials highlight their efficacy in reducing heart failure (HF) hospitalizations and cardiovascular (CV) mortality. Integrating SGLT2 inhibitors into cardio-oncology protocols could revolutionize the management of CTRCD, enhancing patient outcomes in oncology and cardiovascular care. Considering the emerging evidence, SGLT2 inhibitors may provide significant benefits to patients undergoing anthracycline therapy, particularly those with elevated cardiovascular risk profiles. We recommend that future prospective, large-scale clinical trials further evaluate the efficacy and safety of these agents as cardioprotective therapy to optimize individualized treatment strategies.

Pollution caused by plastic materials has a great impact on the environment. The biodegradation process is a good treatment solution for common polymers and biodegradation susceptible ones. The present work introduces new insight into the biodegradation process from a mathematical point of view, as it envisions a new empirical model for this complex process. The model is an exponential function with two different time constants and a time delay, which follows the weight loss profile of the polymer during the biodegradation process. Moreover, this function can be generated as the output variable of a dynamic exogenous system described through state equations. The newly developed models displayed a good fit against the experimental data, as shown by statistical indicators. In addition, the new empirical model was compared to kinetics models available in the literature and the correlation coefficients were closest to 1 for the new empirical model in all discussed cases. The mathematical operations were performed in the MATLAB Simulink environment.